Abstract: The present disclosure provides pharmaceutical compositions comprising a cannabinoid, and dosage forms comprising same, for oral delivery, such as sublingual or buccal delivery. The compositions of the present disclosure are substantially homogeneous and remain stable and monophasic upon storage. Also provided are methods of using the compositions for pain management and to treat various diseases and conditions, including dementia, sleep disorders, movement disorders, mental disorders, and multiple sclerosis.

Abstract: A capacity booster cell and control method thereof are provided. The capacity booster cell provides a communication service for at least one terminal apparatus based on an active mode, an energy saving transition mode, and an energy saving mode. In the active mode, the capacity booster cell determines whether to switch to the energy saving transition mode based on a predicted load information. In the energy saving transition mode, the capacity booster cell hands over the communication service of the at least one terminal apparatus to at least one neighbor cell. In response to completing handing over the communication service of the at least one terminal apparatus, the capacity booster cell is switched to the energy saving mode, wherein the capacity booster cell in the energy saving mode is suspended from providing the communication service.

Abstract: The invention provides emulsion compositions comprising at least one cannabinoid compound, and methods for making the same. The emulsion compositions are stable, well tolerated and are capable of delivering therapeutically effective amounts of cannabinoids to target sites, including sites on the surface of and/or within an eye. Also provided are methods of using the compositions to provide ocular neuroprotection and/or to treat ophthalmic conditions such as glaucoma.

Abstract: The present disclosure provides pharmaceutical compositions comprising a cannabinoid, and dosage forms comprising same, for oral delivery, such as sublingual or buccal delivery. The compositions of the present disclosure are substantially homogeneous and remain stable and monophasic upon storage. Also provided are methods of using the compositions for pain management and to treat various diseases and conditions, including dementia, sleep disorders, movement disorders, mental disorders, and multiple sclerosis.

Abstract: The invention provides emulsion compositions comprising at least one cannabinoid compound, and methods for making the same. The emulsion compositions are stable, well tolerated and are capable of delivering therapeutically effective amounts of cannabiniods to target sites, including sites on the surface of and/or within an eye. Also provided are methods of using the compositions to provide ocular neuroprotection and/or to treat ophthalmic conditions such as glaucoma.

Abstract: Disclosed is a heart rate monitoring system containing a machine learning platform containing self-learning and/or personalizable algorithms capable of detecting and filtering out artifacts in signals indicative of an individual's heart rate, such signals generated from one or more electrocardiogram sensors. The self-learning and/or personalizable algorithms are updated periodically. Accordingly, the machine learning platform improves its accuracy in detecting and/or rejecting/filtering out artifacts and/or becomes more personalized as further signals indicative of an individual's heart rate are processed. The machine learning platform performs detection and filtering out of artifacts via dimension reduction algorithms. The system further contains a first algorithm for real time measurement of heart rate variability (HRV). Also disclosed is a heart rate monitoring method that implements a heart rate monitoring system disclosed herein.

Abstract: The present disclosure provides pharmaceutical compositions comprising a cannabinoid, and dosage forms comprising same, for oral delivery, such as sublingual or buccal delivery. The compositions of the present disclosure are substantially homogeneous and remain stable and monophasic upon storage. Also provided are methods of using the compositions for pain management and to treat various diseases and conditions, including dementia, sleep disorders, movement disorders, mental disorders, and multiple sclerosis.

Abstract: The present disclosure provides pharmaceutical compositions comprising a cannabinoid, and dosage forms comprising same, for oral delivery, such as sublingual or buccal delivery. The compositions of the present disclosure are substantially homogeneous and remain stable and monophasic upon storage. Also provided are methods of using the compositions for pain management and to treat various diseases and conditions, including dementia, sleep disorders, movement disorders, mental disorders, and multiple sclerosis.

Abstract: This invention relates to novel opioid derivatives of Formula I: or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R3, R4 and Z are as defined herein in the disclosure. The invention also relates to the use of such compounds for the treatment or prevention of, for example, pain.

Abstract: The invention provides emulsion compositions comprising at least one cannabinoid compound, and methods for making the same. The emulsion compositions are stable, well tolerated and are capable of delivering therapeutically effective amounts of cannabiniods to target sites, including sites on the surface of and/or within an eye. Also provided are methods of using the compositions to provide ocular neuroprotection and/or to treat ophthalmic conditions such as glaucoma.

Abstract: The invention provides emulsion compositions comprising at least one cannabinoid compound, and methods for making the same. The emulsion compositions are stable, well tolerated and are capable of delivering therapeutically effective amounts of cannabiniods to target sites, including sites on the surface of and/or within an eye. Also provided are methods of using the compositions to provide ocular neuroprotection and/or to treat ophthalmic conditions such as glaucoma.

Abstract: The present invention provides pharmaceutical compositions and methods for use and manufacture thereof. The pharmaceutical compositions comprise a therapeutically effective amount of a cannabinoid or a pharmaceutically acceptable salt or solvate thereof and an amphiphilic copolymer comprising at least one hydrophilic component and at least one hydrophobic component. The cannabinoid is encapsulated in the amphiphilic copolymer, and the composition is suitable for intranasal or inhalation delivery.

Abstract: The invention provides emulsion compositions comprising at least one cannabinoid compound, and methods for making the same. The emulsion compositions are stable, well tolerated and are capable of delivering therapeutically effective amounts of cannabiniods to target sites, including sites on the surface of and/or within an eye. Also provided are methods of using the compositions to provide ocular neuroprotection and/or to treat ophthalmic conditions such as glaucoma.

Abstract: The present disclosure provides pharmaceutical compositions comprising a cannabinoid, and dosage forms comprising same, for oral delivery, such as sublingual or buccal delivery. The compositions of the present disclosure are substantially homogeneous and remain stable and monophasic upon storage. Also provided are methods of using the compositions for pain management and to treat various diseases and conditions, including dementia, sleep disorders, movement disorders, mental disorders, and multiple sclerosis.

Abstract: This invention relates to novel opioid derivatives of Formula I: or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R3, R4 and Z are as defined herein in the disclosure. The invention also relates to the use of such compounds for the treatment or prevention of, for example, pain.

Abstract: A composite article includes an inorganic non-metallic article and a resin article. The resin article is connected to the inorganic non-metallic article. The inorganic non-metallic article includes at least one connecting surface. At least a portion of the connecting surface comprises groove-peak like microstructures. At least one of the microstructures comprises a rough and/or porous surface having at least one of a roughness element and a porous structure. The inorganic non-metallic article and resin article are combined together through the microstructures. A method for making the composite article is also provided.

Abstract: A composite article includes an inorganic non-metallic article, a resin article, and a connecting layer located between the inorganic non-metallic article and the resin article. The connecting layer is configured to connect the inorganic non-metallic article and the resin article together. A surface of the connecting layer connected with the resin article includes a plurality of microstructures, a portion of the resin article fills in the plurality of microstructures. A method for making the composite article is also provided.

Abstract: A vapor deposition device using a lift-off process includes an evaporation source, a support frame mounted for rotation about a first axis that passes through the evaporation source, a central dome-shaped wafer holder mounted to the support frame wherein a centerpoint of the central dome-shaped wafer holder is aligned with the first axis, an orbital dome-shaped wafer holder mounted to the support frame in a position offset from the first axis and rotatable about a second axis that passes through a centerpoint of the orbital dome-shaped wafer holder and the evaporation source, and a plurality of wafer positions on the central dome-shaped wafer holder and the orbital dome-shaped wafer holder where each of the wafer positions are offset from the first axis and the second axis.

Abstract: The present invention provides a method for combining a fluid delivery system with an analysis system for performing immunological or other chemical of biological assays. The method comprises a miniature plastic fluidic cartridge containing a reaction chamber with a plurality of immobilized species, a capillary channel, and a pump structure along with an external linear actuator corresponding to the pump structure to provide force for the fluid delivery. The plastic fluidic cartridge can be configured in a variety of ways to affect the performance and complexity of the assay performed.

Abstract: A vapor deposition device using a lift-off process includes an evaporation source, a space frame mounted for rotation about a first axis that passes through the evaporation source, a central dome-shaped wafer holder mounted to the space frame wherein a centerpoint of the central dome-shaped wafer holder is aligned with the first axis, a orbital dome-shaped wafer holder mounted to the space frame in a position offset from the first axis and rotatable about a second axis that passes through a centerpoint of the orbital dome-shaped wafer holder and the evaporation source, and a plurality of wafer positions on the central dome-shaped wafer holder and the orbital dome-shaped wafer holder where each of the wafer positions are offset from the first axis and the second axis.